PA Medical News about Arthritis Pain Viscosupplementation

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
New Certification for Hermatology-Oncology Coding

Dorothy J. Schirf, MD

Technology Advances

Targeted Melanoma Therapy May Derive From the Deep

Sara Hartley

Cancer Science

Low Sugar Environment Promotes Oncogenic Mutations

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Viscosupplementation Treatment of Arthritis Pain
Current Pain and Headache Reports, 11/06/09

Benke M et al. – Viscosupplementation, in which hyaluronic acid (HA) is injected into the knee joint, has evolved into an important part of our current therapeutic regimen in addressing the patient with knee pain due to osteoarthritis (OA). Although suffering from lack of an “evidence–based” approach, and largely funded by industry, there is a growing body of outcome data demonstrating the efficacy of HA in decreasing pain and improving function in patients with knee OA, although no evidence indicates that HA is in any way chondroprotective. The clinical success of HA has led to the ongoing introduction of various forms of HA, although little data are available to justify one over the other.

<< Previous
Viral obesity: fact or fiction?

Next >>
Enhanced Pain Perception in Rheumatoid Arthritis: Novel...